Braidwell LP Decreases Stock Position in Dyne Therapeutics, Inc. $DYN

Braidwell LP decreased its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 16.6% during the third quarter, Holdings Channel.com reports. The fund owned 2,730,481 shares of the company’s stock after selling 542,868 shares during the period. Braidwell LP’s holdings in Dyne Therapeutics were worth $34,541,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. ArrowMark Colorado Holdings LLC grew its position in Dyne Therapeutics by 2.0% during the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 785,915 shares of the company’s stock worth $9,942,000 after purchasing an additional 15,690 shares during the last quarter. Alliancebernstein L.P. increased its stake in Dyne Therapeutics by 8.6% during the 3rd quarter. Alliancebernstein L.P. now owns 106,680 shares of the company’s stock valued at $1,350,000 after purchasing an additional 8,440 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in shares of Dyne Therapeutics by 48.3% in the third quarter. Ameriprise Financial Inc. now owns 422,656 shares of the company’s stock worth $5,347,000 after buying an additional 137,652 shares during the last quarter. Creative Planning raised its holdings in shares of Dyne Therapeutics by 6.8% in the third quarter. Creative Planning now owns 15,527 shares of the company’s stock worth $196,000 after buying an additional 986 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC lifted its stake in shares of Dyne Therapeutics by 24.7% during the third quarter. Schonfeld Strategic Advisors LLC now owns 415,927 shares of the company’s stock worth $5,261,000 after buying an additional 82,474 shares during the period. Institutional investors and hedge funds own 96.68% of the company’s stock.

Insiders Place Their Bets

In other Dyne Therapeutics news, Director Brian S. Posner purchased 3,000 shares of the stock in a transaction on Friday, March 6th. The shares were bought at an average price of $15.06 per share, for a total transaction of $45,180.00. Following the completion of the transaction, the director owned 11,500 shares of the company’s stock, valued at $173,190. This trade represents a 35.29% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders own 14.14% of the company’s stock.

Analyst Upgrades and Downgrades

DYN has been the topic of a number of research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Wednesday, January 21st. JPMorgan Chase & Co. lowered their price target on Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating for the company in a research report on Tuesday, January 20th. Morgan Stanley dropped their price target on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a research note on Monday, March 2nd. Sanford C. Bernstein set a $23.00 price objective on Dyne Therapeutics in a report on Tuesday, December 9th. Finally, Oppenheimer upgraded Dyne Therapeutics from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $11.00 to $40.00 in a research note on Wednesday, December 10th. Three research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Dyne Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $35.14.

Dyne Therapeutics Stock Down 0.8%

DYN opened at $17.92 on Friday. Dyne Therapeutics, Inc. has a fifty-two week low of $6.36 and a fifty-two week high of $25.00. The company has a debt-to-equity ratio of 0.15, a quick ratio of 22.25 and a current ratio of 22.25. The company has a fifty day moving average of $16.99 and a two-hundred day moving average of $17.29. The stock has a market capitalization of $2.96 billion, a price-to-earnings ratio of -5.06 and a beta of 1.34.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Monday, March 2nd. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.02). On average, research analysts expect that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.